The following is a list of publications co-authored by GSID researchers and our colleagues. For complete citations, please download a print
version here.

Authors - Short Title Publication Year Field GSID Author(s)
Shubin et al Additional boosting to the RV144 vaccine regimen increased Fc-mediated effector function magnitude but not durability AIDS. 2023 Aug 1;37(10):1519-1524 2023 HIV Faruk Sinangil
Costanzo et al ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone JCI Insight. 2023;8(9):e167664 2023 HIV Faruk Sinangil
Sironi et al No association of a risk variant for severe COVID-19 with HIV protection in three cohorts of highly exposed individuals PNAS Nexus, 2022, 1, 1–4 2022 HIV, COVID-19 Faruk Sinangil
Meza et al IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men Virulence, 2022 Dec;13(1):757-763 2022 HIV Faruk Sinangil
Huang et al AIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period Vaccine,Volume 39, Issue 33, 30 July 2021, Pages 4641-4650 , 2021 HIV Carter Lee, Vineeta Gulati, Faruk Sinangil
Pitisuttithum et al Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. Lancet HIV. 2020 Feb 6. pii: S2352-3018(19)30406-0. doi: 10.1016/S2352-3018(19)30406-0. 2020 HIV Faruk Sinangil
Easterhoff et al Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. J Virol. 2020 Jan 31;94(4). pii: e01120-19. doi: 10.1128/JVI.01120-19. 2020 HIV Faruk Sinangil
Easterhoff et al HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. JCI Insight. 2020 Jan 30;5(2). pii: 131437. doi: 10.1172/jci.insight.131437. 2020 HIV Faruk Sinangil
Meza et al Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine. AIDS. 2020 Jan 1;34(1):25-32. doi: 10.1097/QAD.0000000000002401 2020 HIV Faruk Sinangil, Keith Higgins
Rouphael et al DNA priming and gp120 boosting induces HIV-specific antibodies in a randomized clinical trial. J Clin Invest. 2019 Nov 1;129(11):4769-4785. doi: 10.1172/JCI128699 2019 HIV Faruk Sinangil
Pantaleo et al Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial The Lancet HIV. 2019; 6(11): PE737-E749. doi: 10.1016/S2352-3018(19)30262-0 2019 HIV Carter Lee
Gray et al Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 Sep 18;11(510). pii: eaax1880. doi: 10.1126/scitranslmed.aax1880. 2019 HIV Faruk Sinangil, Carter Lee
Mesa et al Ancestral sequences from an elite neutralizer proximal to the development of neutralization resistance as a potential source of HIV vaccine immunogens. PLoS One. 2019 Apr 10;14(4):e0213409. doi: 10.1371/journal.pone.0213409. eCollection 2019 2019 HIV Faruk Sinangil
Akapirat et al Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. PLoS One. 2018 Apr 27;13(4):e0196397. doi: 10.1371/journal.pone.0196397. eCollection 2018. 2018 HIV Faruk Sinangil
Balasubramanian et al Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials. Sci Rep. 2018 Jan 11;8(1):542. doi: 10.1038/s41598-017-18863-0. 2018 HIV Faruk Sinangil, Keith Higgins
Gilbert et al Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women PLOS ONE 12(5): e0176428. 2017 HIV Don Francis, Carter Lee, and Faruk Sinangil
Rerks-Ngarm et al Randomized, Double Blind Evaluation of Late Boost Strategies for HIV-uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial J Infect Dis. 2017 Feb 21. doi: 10.1093/infdis/jix099. 2017 HIV Faruk Sinangil
Balasubramanian et al Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination Vaccine. 2017 Feb 6. pii: S0264-410X(17)30089-0. doi: 10.1016/j.vaccine.2016.11.107. 2017 HIV Faruk Sinangil, Keith Higgins
Easterhoff et al Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial PLoS Pathog 13(2): e1006182. doi:10.1371/journal.ppat.1006182 2017 HIV Faruk Sinangil
Karnasuta et al Comparison of Antibody Responses Induced by RV144, VAX003 and VAX004 Vaccination Regimens. 2017 HIV Faruk Sinangil, Don Francis
Luo et al Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight. 2016 Dec 8;1(20):e88522. DOI: 10.1172/jci.insight.88522 2016 HIV Faruk Sinangil, Don Francis, Carter Lee
Mahan et al Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination PLoS Pathog 12(3): e1005456. doi: 10.1371/journal.ppat.1005456 2016 HIV Don Francis
Karasavvas et al IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. AIDS Research and Human Retroviruses. 2015;31(11):1178-1186. doi:10.1089/aid.2015.0034. 2015 HIV Faruk Sinangil, Don Francis
Wiehe et al Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. Immunity. 2014;41(6):909-918. doi:10.1016/j.immuni.2014.11.014. 2014 HIV Faruk Sinangil
Dell et al Field evaluation of a camera-based mobile health system in low-resource settings. In Proceedings of the 16th international conference on Human-computer interaction with mobile devices & services (MobileHCI '14). ACM, New York, NY, USA, 33-42. DOI=10.1145/2628363.2628366 2014 mHealth Ian Francis
Chung et al Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines Sci Transl Med 19 March 2014: ( 6/ 228: 228-38)
Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007736 
2014 HIV Don Francis
Arita et al Variola Viruses Chapter 21 in Manual of Security Sensitive Microbes and Toxins, Ed. Don Liu. CRC Press 2014. 2014 Smallpox Don Francis
Arita et al Is it time to destroy the smallpox virus? Science 29 August 2014: 1010. DOI:10.1126/science.345.6200.1010-a 2014 Smallpox Don Francis
Francis et al Global Vaccine Supply - the increasing role of manufacturers from middle income countries Vaccine 32: 5259-5265; 2014 2014 General Don Francis
Penezina et al Performance of a Redesigned HIV Selectest Enzyme-Linked Immunosorbent Assay Optimized To Minimize Vaccine-Induced Seropositivity in HIV Vaccine Trial Participants Clin Vaccine Immunol March 2014 vol. 21 no. 3 391-398  2014 HIV Keith Higgins
Yates et al Vaccine-Induced Env V1/V2 IgG3 Correlate with Lower HIV-Infection Risk and Declines Soon After Vaccination Sci Transl Med 19 March 2014:
Vol. 6, Issue 228, p. 228ra39
Sci. Transl. Med. DOI: 10.1126/scitranslmed.3007730 
2014 HIV Don Francis, Carter Lee, and Faruk Sinangil
Dubin et al Closing the circle: a thirty-year retrospective on the AIDS/blood epidemic.  Transfusion, 2013, Vol 53 (9), DOI: 10.1111/trf.12374 2013 HIV Don Francis
Gottardo et al Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial PLoS One. 2013 Sep 26;8(9):e75665. doi: 10.1371/journal.pone.0075665. eCollection 2013. 2013 HIV Don Francis, Carter Lee, and Faruk Sinangil
Alam et al Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletion. J Virol. 2013 Feb;87(3):1554-68. doi: 10.1128/JVI.00718-12. Epub 2012 Nov 21. 2013 HIV Faruk Sinangil
Liao et al Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2 Immunity - 24 January 2013 (Vol. 38, Issue 1, pp. 176-186).  doi: 10.1016/j.immuni.2012.11.011 2013 HIV Faruk Sinangil
O'Rourke et al Sequences in glycoprotein gp41, the CD4 binding site, and the V2 domain regulate sensitivity and resistance of HIV-1 to broadly neutralizing antibodies. J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29. 2012 HIV Faruk Sinangil
Francis Deadly AIDS policy failure by the highest levels of the US government: a personal look back 30 years later for lessons to respond better to future epidemics.  Journal of Public Health Policy (2012) 33, 290–300. doi:10.1057/jphp.2012.14 2012 HIV Don Francis
Francis Protecting the public’s health: remove the political constraints that hamper the Centers for Disease Control and Prevention. AIDS. 2012 Jun 1;26(9):1175-6. doi:10.1097/QAD.0b013e32835392dd 2012 General Don Francis
Karasavvas et al The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120 AIDS Research and Human Retroviruses. November 2012, 28(11): 1444-1457. doi: 10.1089/aid.2012.0103 2012 HIV Faruk Sinangil
Mahoney et al Cost of production of live attenuated dengue vaccines: A case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine, Volume 30, Issue 32, 6 July 2012, Pages 4892-4896, ISSN 0264-410X, 10.1016/j.vaccine.2012.02.064. 2012 Dengue Don Francis
Montefiori et al Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. J Infect Dis. (2012) 206(3): 431-441. doi:10.1093/infdis/jis367 2012 HIV Don Francis, Carter Lee, and Faruk Sinangil
O'Rourke et al Sequences in Glycoprotein gp41, the CD4 Binding Site, and the V2 Domain Regulate Sensitivity and Resistance of HIV-1 to Broadly Neutralizing Antibodies. J Virol. 2012 Nov;86(22):12105-14. doi: 10.1128/JVI.01352-12. Epub 2012 Aug 29. 2012 HIV Faruk Sinangil
Rerks-Ngarm et al Extended Evaluation of the Virologic, Immunologic, and Clinical Course of Volunteers Who Acquired HIV-1 Infection in a Phase III Vaccine Trial of ALVAC-HIV and AIDSVAX B/E. J Infect Dis. first published online July 26, 2012 doi:10.1093/infdis/jis478 2012 HIV Don Francis
Robb et al Risk behavior and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144. The Lancet Infectious Diseases, Volume 12, Issue 7, Pages 531 - 537, July 2012. DOI: 10.1016/S1473-3099(12)70088-9 2012 HIV Don Francis
Alam et al Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen is Enhanced by a gp120 N-terminal Deletion J. Virol. February 2013 87:3 1554-1568; published ahead of print 21 November 2012, doi:10.1128/JVI.00718-12 2012 HIV Faruk Sinangil
Stephenson et al Preexisting Adenovirus Seropositivity Is Not Associated With Increased HIV-1 Acquisition in Three HIV-1 Vaccine Efficacy Trials. J Infect Dis. (2012) 205(12): 1806-1810 first published online April 5, 2012 doi:10.1093/infdis/jis285 2012 HIV Faruk Sinangil
Arita et al Safe landing for global polio eradication: A Perspective.  Vaccine. 29 (2011) 8827-34. doi:10.1016/j.vaccine.2011.09.059 2011 Polio Don Francis
Barouch et al International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011 Jul 18;29 (32):5203-9. Epub 2011 May 25. doi:10.1016/j.vaccine.2011.05.025 2011 HIV Faruk Sinangil
Bonsignori et al Analysis of a Clonal Lineage of HIV-1 Envelope V2/V3 Conformational Epitope-Specific Broadly Neutralizing Antibodies and Their Inferred Unmutated Common Ancestors.  J Virol. 2011 Oct;85(19):9998-10009. Epub 2011 Jul 27. doi:10.1128/JVI.05045-11 2011 HIV Faruk Sinangil
Francis et al WHO Influenza vaccine technology transfer initiative:  Role and activities of the Technical Advisory Group. Vaccine 295 (2011) A45-A47. doi:10.1016/j.vaccine.2011.02.078 2011 Influenza Don Francis
Mahoney et al Dengue vaccines regulatory pathways: A report on two meetings with regulators of developing countries. PLoS Med 8(2): e1000418. Published February 22, 2011. doi:10.1371/journal.pmed.1000418. 2011 Dengue Don Francis
Bonsignori et al Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011 Oct;85(19):9998-10009. doi: 10.1128/JVI.05045-11. Epub 2011 Jul 27. 2011 HIV Faruk Sinangil
Barouch et al International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine. 2011 Jul 18;29(32):5203-9. doi: 10.1016/j.vaccine.2011.05.025. Epub 2011 May 25. 2011 HIV Faruk Sinangil
Perez-Losada et al Phylodynamics of HIV-1 from a Phase III AIDS Vaccine Trial in Bangkok, Thailand. PLoS One. 2011 Mar 10;6(3):e16902. doi:10.1371/journal.pone.0016902 2011 HIV Faruk Sinangil
Pitisuttihum et al Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. PLoS Vol 6, Issue 12, e27837, December 2011.  doi:10.1371/journal.pone.0027837 2011 HIV Don Francis
MOPH-TAVEG Screening and evaluation of potential volunteers for a phase III trial in Thailand of a candidate preventive HIV vaccine (RV148). Vaccine 29 (2011) 4285-4292. doi:10.1016/j.vaccine.2011.03.014 2011 HIV Don Francis
Francis Successes and failures: Worldwide vaccine development and application. Biologicals. 2010 Sep;38(5):523-8. Epub 2010 Aug 4. Review. doi:10.1016/j.biologicals.2010.06.003 2010 General Don Francis
Francis et al The manufacture and supply of dengue vaccine.   Occasional Paper, Pediatric Dengue Vaccine Initiative, International Vaccine Institute, December 2010. 2010 Dengue Don Francis
Gilbert et al Magnitude and breadth of a non-protective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis 202 (4): 595-605 (2010). doi: 10.1086/654816 2010 HIV Faruk Sinangil
O'Rourke et al Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol. 2010 Nov;84(21):11200-9. doi:10.1128/JVI.00790-10 2010 HIV Faruk Sinangil
Perez-Losada et al Phylodynamics of HIV-1 from a phase-III AIDS vaccine trial in North America. Mol Biol Evol 27(2):417-25 (2010). doi: 10.1093/molbev/msp254 2010 HIV Faruk Sinangil
Smith et al Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies.  PLoS One 5(8): e12076 (2010). Doi:1371/journal.pone.0012076 2010 HIV Faruk Sinangil
O'Rourke et al Novel ring structure in the gp41 trimer of human deficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J Virol. 83(15):7728-38 (2009). doi:10.1128/JVI.00688-09 2009 HIV Faruk Sinangil
Perez-Losada et al Ethnic differences in the adaptation rate of HIV gp120 from a vaccine trial. Retrovirology 6:67 (2009). doi:10.1186/1742-4690-6-67 2009 HIV Faruk Sinangil
Rerks-Ngarm et al Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009 Dec 3;361(23):2209-20. Epub 2009 Oct 20. doi:10.1056/NEJMoa0908492 2009 HIV Don Francis
Pitisuttihum et al Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. J Med Assoc Thai. 2007 Nov;90(11):2442-8. 2007 HIV Don Francis
Jobes et al High incidence of unusual cysteine variants in gp120 envelope proteins from early HIV-1 infections from a Phase 3 vaccine efficacy trial. AIDS Res Hum Retroviruses 22 (10):1014-21 (2006). doi:10.1089/aid.2006.22.1014 2006 HIV Faruk Sinangil
Jobes et al Longitudinal population analysis of dual infection with recombination in two strains of HIV-1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial. AIDS Res Hum Retroviruses 22 (10): 968-78 (2006). doi:  10.1089/aid.2006.22.968 2006 HIV Faruk Sinangil



© 2006-2022 Global Solutions for Infectious Diseases, All Rights Reserved